| # | Title | Journal | Year | Citations |
|---|
| 1 | Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC | New England Journal of Medicine | 2018 | 2,808 |
| 2 | RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer | Journal of Clinical Oncology | 2011 | 932 |
| 3 | Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma | Cancer | 2003 | 836 |
| 4 | A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses | Breast Cancer Research and Treatment | 2008 | 732 |
| 5 | Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing | Science Translational Medicine | 2012 | 557 |
| 6 | Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial | Lancet Oncology, The | 2018 | 530 |
| 7 | A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer | British Journal of Cancer | 2002 | 514 |
| 8 | MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer | Clinical Cancer Research | 2017 | 492 |
| 9 | Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) | Journal of Clinical Oncology | 2020 | 478 |
| 10 | Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab | Journal of Surgical Oncology | 2005 | 471 |
| 11 | Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer | Journal of Clinical Oncology | 2001 | 451 |
| 12 | The Global Breast Cancer Burden: Variations in Epidemiology and Survival | Clinical Breast Cancer | 2005 | 445 |
| 13 | Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer | Annals of Oncology | 2021 | 393 |
| 14 | Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases | Annals of Oncology | 2018 | 388 |
| 15 | Clinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 Years | Pediatrics | 2013 | 384 |
| 16 | Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy | International Journal of Radiation Oncology Biology Physics | 2003 | 373 |
| 17 | Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 | Science Immunology | 2020 | 304 |
| 18 | A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer | Annals of Oncology | 2005 | 286 |
| 19 | Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer | Annals of Oncology | 2001 | 284 |
| 20 | Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial | Cancer Research | 2000 | 284 |
| 21 | Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development | Clinical Cancer Research | 2002 | 280 |
| 22 | Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients | Cancer Gene Therapy | 2003 | 277 |
| 23 | Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity | Gene Therapy | 2001 | 262 |
| 24 | Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer | Nature Communications | 2019 | 252 |
| 25 | Granulocyte-Macrophage Colony-Stimulating Factor Gene-Modified Autologous Tumor Vaccines in Non-Small-Cell Lung Cancer | Journal of the National Cancer Institute | 2004 | 239 |
| 26 | Effect of Dosing Frequency on Bisphosphonate Medication Adherence in a Large Longitudinal Cohort of Women | Mayo Clinic Proceedings | 2005 | 233 |
| 27 | Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer | Breast Cancer Research and Treatment | 2010 | 232 |
| 28 | Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study | Annals of Oncology | 2021 | 225 |
| 29 | Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study | International Journal of Gynecological Cancer | 2005 | 219 |
| 30 | A phase III randomized evaluation of amifostine in stage IIIA/IIIB non[ndash ]small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: Preliminary findings | Seminars in Oncology | 2002 | 200 |
| 31 | TNFerade Biologic, an Adenovector With a Radiation-Inducible Promoter, Carrying the Human Tumor Necrosis Factor Alpha Gene: A Phase I Study in Patients With Solid Tumors | Journal of Clinical Oncology | 2004 | 198 |
| 32 | First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients | Annals of Oncology | 2013 | 195 |
| 33 | Emerging targeted therapies in triple-negative breast cancer | Annals of Oncology | 2012 | 174 |
| 34 | Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. | Cancer Research | 2009 | 172 |
| 35 | The New Bisphosphonate, Zometa®(Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate | Cancer Investigation | 2002 | 170 |
| 36 | Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with Taxanes | Clinical Breast Cancer | 2007 | 164 |
| 37 | Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA) | International Journal of Radiation Oncology Biology Physics | 2017 | 163 |
| 38 | Improved quality of life for romiplostim‐treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo‐controlled trials | British Journal of Haematology | 2009 | 150 |
| 39 | Cost Effectiveness of Evidence-Based Treatment Guidelines for the Treatment of Non–Small-Cell Lung Cancer in the Community Setting | Journal of Oncology Practice | 2010 | 149 |
| 40 | The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients | American Journal of Hematology | 2009 | 146 |
| 41 | Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer | Annals of Oncology | 2021 | 146 |
| 42 | Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2023 | 135 |
| 43 | Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil | Annals of Oncology | 2002 | 132 |
| 44 | Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update | Blood | 2008 | 130 |
| 45 | Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial | Annals of Oncology | 2021 | 130 |
| 46 | Rationale for a phase III study of erythropoietin as a neurocognitive protectant in patients with lung cancer receiving prophylactic cranial irradiation | Seminars in Oncology | 2002 | 130 |
| 47 | A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma | Molecular Therapy | 2011 | 129 |
| 48 | Ethical Beliefs of Business Professionals: A Study of Gender, Age and External Factors | Journal of Business Ethics | 2001 | 123 |
| 49 | A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the baylor experience) | Annals of Surgical Oncology | 2000 | 119 |
| 50 | Cognitive Effects of Cancer and Its Treatments at the Intersection of Aging: What Do We Know; What Do We Need to Know? | Seminars in Oncology | 2013 | 119 |
